Androgenetic Alopecia in Fabry Disease
| Status: | Completed |
|---|---|
| Conditions: | Hematology, Dermatology, Metabolic |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Hematology, Pharmacology / Toxicology |
| Healthy: | No |
| Age Range: | 18 - 64 |
| Updated: | 4/21/2016 |
| Start Date: | December 2010 |
| End Date: | October 2015 |
The purpose of this study is to assess whether patients with the classic form of Fabry
disease have significantly less androgenic alopecia (male pattern baldness).
disease have significantly less androgenic alopecia (male pattern baldness).
Objectives: To test the hypothesis that adult males with classic form of Fabry disease have
a significantly lower incidence of androgenic alopecia than matched controls.
Study Population: 120 patients aged 20-64 with Fabry disease that have GLA mutations or
alpha-galactosidase A activity associated with no residual enzyme activity and non-Fabry
male controls of the same age range and the same number of non-Fabry controls.
Design: This is a cross-sectional study comparing the prevalence of androgenic alopecia in
two groups of subjects.
Outcome Measures: The levels of the outcome will be no androgenic alopecia and frontal only
androgenetic alopecia opposed to vertex only and frontal and vertex androgenetic alopecia.
a significantly lower incidence of androgenic alopecia than matched controls.
Study Population: 120 patients aged 20-64 with Fabry disease that have GLA mutations or
alpha-galactosidase A activity associated with no residual enzyme activity and non-Fabry
male controls of the same age range and the same number of non-Fabry controls.
Design: This is a cross-sectional study comparing the prevalence of androgenic alopecia in
two groups of subjects.
Outcome Measures: The levels of the outcome will be no androgenic alopecia and frontal only
androgenetic alopecia opposed to vertex only and frontal and vertex androgenetic alopecia.
Inclusion Criteria:
- Male patients with Fabry disease age 20-64 years old.
- Healthy male controls age 20-64 years old
- GLA gene mutations associated with the classic form of Fabry disease or having
alpha-galactosidase A activity that is essentially zero
- Patients who freely agree to participate in this study and understand the nature,
risks and benefits of this study and give their written informed consent.
We found this trial at
1
site
Baylor University Medical Center Baylor University Medical Center in Dallas, TX is ranked nationally in...
Click here to add this to my saved trials
